With a Coronavirus Vaccine On the Horizon, Is DocuSign Stock a Buy?
DocuSign (NASDAQ: DOCU) was one of the undisputed winners of 2019, with its shares jumping 85%. The stock has continued its stratospheric rise in 2020, as the pivot to remote work caused by the pandemic drove ever-increasing demand for digitally signed documents and agreement management, making it one of the year's top performers.
However, with not one, but two effective coronavirus vaccines on the fast track for approval, DocuSign is one of a number of high-flying stocks that have dipped, losing more than 20% of its value in less than two months. This has many investors wondering if this is a buying opportunity or if there's more carnage to come.
Image source: DocuSign.
Source Fool.com
